<DOC>
	<DOCNO>NCT01563614</DOCNO>
	<brief_summary>The purpose trial test safety tolerance combination therapy cytarabine , lomustine radiotherapy patient leptomeningeal metastasis malignant melanoma .</brief_summary>
	<brief_title>A Clinical Trial Assess Safety &amp; Efficacy Treatment Patients With Metastasis From Malignant Melanoma - Treatment Consists Substances Lomustine ( Capsules ) &amp; Cytarabine ( Injected Into Area Near Spinal Cord ) , Accompanied Radiotherapy Brain</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Malignant melanoma ( include melanoma unknown primary site , recurrent pretreated systemic melanoma and/or melanoma parenchymal CNS metastasis ) leptomeningeal metastasis demonstrate positive CSF ( cerebrospinal liquor ) cytology AND/OR presence characteristic sign symptom leptomeningeal metastasis support MRI scan indicate presence meningeal tumour CSF flow abnormality must exclude Males female â‰¥ 18 year age Karnofsky Performance Status &gt; 50 % Adequate organ function ( adequate bone marrow reserve , adequate liver function , adequate renal function . adequate blood clot ) Unresected parenchymal brain metastasis diameter &gt; 3 cm Prior non melanoma malignancy ( unless adequately treat carcinoma situ cervix non melanoma skin cancer ) Prior intrathecal chemotherapy Prior treatment systemic cytarabine nitrosureas The patient ist pregnant breast feeding Severe , active comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>